Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
259 hedge funds and large institutions have $2.74B invested in Amicus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 97 increasing their positions, 78 reducing their positions, and 64 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 78
23% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $21.6M
1.12% less ownership
Funds ownership: 107.19% → 106.07% (-1.1%)
5% less funds holding
Funds holding: 273 → 259 (-14)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 64
58% less capital invested
Capital invested by funds: $6.45B → $2.74B (-$3.71B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$61.5M |
| 2 |
JP Morgan Chase
New York
|
+$53M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$50.3M |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$49.6M |
| 5 |
DM
Deerfield Management
New York
|
+$41.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$154M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$48.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$48.7M |
| 4 |
Morgan Stanley
New York
|
-$42.8M |
| 5 |
D.E. Shaw & Co
New York
|
-$41.2M |
FOLD Hedge Fund Activity: Q1 2021 in Review
259 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2021, worth a combined $2.74B — down 58% from $6.45B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of FOLD and 52 opened new positions — a net loss of 12 holders — while 78 trimmed existing stakes and 97 added.
The largest buyer was Wellington Management Group, adding an estimated $61.5M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $154M sold.
- 259 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2021, down from 273 in Q4 2020.
- Funds reported $2.74B of Amicus Therapeutics stock for Q1 2021, down 58% quarter-over-quarter.
- 52 funds opened new Amicus Therapeutics positions in Q1 2021 and 64 closed out, a net change of -12 holders.
- The largest Amicus Therapeutics buyer in Q1 2021 was Wellington Management Group, an estimated $61.5M added.
- The largest Amicus Therapeutics seller in Q1 2021 was Lone Pine Capital, an estimated $154M sold.
Based on aggregated 13F filings for Q1 2021.